Page 129 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 129
YI P0058 SOFOSBUVIR-BASED ANTIVIRAL THERAPY IS HIGHLY ePOSTERS
YI P0059 EFFECTIVE IN RECURRENT HEPATITIS C IN LIVER
YI P0060 TRANSPLANT RECIPIENTS: A “REAL-LIFE” CANADIAN
YI P0061 MULTICENTER EXPERIENCE
YI P0062 Nabiha Faisal*, Marc Bilodeau, Bandar Aljudaibi,
Kevork Peltekian, Eric M. Yoshida, Trana Hussaini,
Peter GhaliStephen E. ConglyMang Ma, Curtis Cooper, Nazia Selzner,
Eberhard L. Renner, Leslie B. Lilly, Canada
META-ANALYSIS: SVR12 WITH SIMEPREVIR AND
SOFOSBUVIR (SMV+SOF) FOR 12 WEEKS IN 225 LIVER
TRANSPLANT (LT) RECIPIENTS WITH HCV GENOTYPE 1
(HCV-1)
Nghia H. Nguyen*, Brittany E. Yee, Glen A. Lutchman, Joseph K. Lim,
Mindie Nguyen, The United States
ANTIVIRAL THERAPY WITH SOFOSBUVIR PLUS RIBAVIRIN
IN HCV-INFECTED CIRRHOTIC PATIENTS AWAITING LIVER
TRANSPLANTATION: PRELIMINARY DATA FROM A SINGLE-
CENTRE EXPERIENCE
Silvia Strona*, Silvia Martini, Daniele Arese, Marco Sacco,
Renato Romagnoli, Francesco Tandoi, Antonio Ottobrelli,
Maria Rosaria Torrani Cerenzia, Federico Balzola, Mauro Salizzoni,
Mario Rizzetto, Italy
TREATMENT WITH NEW ALL-ORAL DIRECT ACTING
ANTIVIRALS IN HCV-RECURRENCE IN LIVER
TRANSPLANT-SETTING INDUCES A REDUCTION OF
IMMUNOSUPPRESSIVE DRUG LEVELS
Joaquín Cabezas*, Marina Berenguer, Juan Manuel Pascasio, María-
Carlota Londoño, José Manuel Sousa Martín, Carmen Navascués,
Carmen Vinaixa, Isolina Baños, José Luis Calleja, Manuel Rodríguez,
Xavier Forns, Javier Crespo, Spain
CHANGES ON CEREBRAL HEMODYNAMICS IN CIRRHOTIC
PATIENTS AFTER LIVER TRANSPLANTATION
Ricardo U. Macias-Rodriguez*, Octavio García Flores, Astrid Ruiz-
Margain, Carlos Cantú-Brito, Aldo Torre, Mexico
Vienna, Austria • April 22–26, 2015 129
YI P0059 EFFECTIVE IN RECURRENT HEPATITIS C IN LIVER
YI P0060 TRANSPLANT RECIPIENTS: A “REAL-LIFE” CANADIAN
YI P0061 MULTICENTER EXPERIENCE
YI P0062 Nabiha Faisal*, Marc Bilodeau, Bandar Aljudaibi,
Kevork Peltekian, Eric M. Yoshida, Trana Hussaini,
Peter GhaliStephen E. ConglyMang Ma, Curtis Cooper, Nazia Selzner,
Eberhard L. Renner, Leslie B. Lilly, Canada
META-ANALYSIS: SVR12 WITH SIMEPREVIR AND
SOFOSBUVIR (SMV+SOF) FOR 12 WEEKS IN 225 LIVER
TRANSPLANT (LT) RECIPIENTS WITH HCV GENOTYPE 1
(HCV-1)
Nghia H. Nguyen*, Brittany E. Yee, Glen A. Lutchman, Joseph K. Lim,
Mindie Nguyen, The United States
ANTIVIRAL THERAPY WITH SOFOSBUVIR PLUS RIBAVIRIN
IN HCV-INFECTED CIRRHOTIC PATIENTS AWAITING LIVER
TRANSPLANTATION: PRELIMINARY DATA FROM A SINGLE-
CENTRE EXPERIENCE
Silvia Strona*, Silvia Martini, Daniele Arese, Marco Sacco,
Renato Romagnoli, Francesco Tandoi, Antonio Ottobrelli,
Maria Rosaria Torrani Cerenzia, Federico Balzola, Mauro Salizzoni,
Mario Rizzetto, Italy
TREATMENT WITH NEW ALL-ORAL DIRECT ACTING
ANTIVIRALS IN HCV-RECURRENCE IN LIVER
TRANSPLANT-SETTING INDUCES A REDUCTION OF
IMMUNOSUPPRESSIVE DRUG LEVELS
Joaquín Cabezas*, Marina Berenguer, Juan Manuel Pascasio, María-
Carlota Londoño, José Manuel Sousa Martín, Carmen Navascués,
Carmen Vinaixa, Isolina Baños, José Luis Calleja, Manuel Rodríguez,
Xavier Forns, Javier Crespo, Spain
CHANGES ON CEREBRAL HEMODYNAMICS IN CIRRHOTIC
PATIENTS AFTER LIVER TRANSPLANTATION
Ricardo U. Macias-Rodriguez*, Octavio García Flores, Astrid Ruiz-
Margain, Carlos Cantú-Brito, Aldo Torre, Mexico
Vienna, Austria • April 22–26, 2015 129
